Fregly M J, Rowland N E
Pharmacol Biochem Behav. 1986 Mar;24(3):721-5. doi: 10.1016/0091-3057(86)90580-0.
The dopamine (DA2) agonist, quinpirole hydrochloride (LY 171555), has been reported to inhibit central presynaptic release of norepinephrine, an effect similar to that of clonidine, an alpha 2-adrenoceptor agonist. Since clonidine exerts an antidipsogenic effect on all types of laboratory-induced drinking, the objective of these experiments was to determine whether administration of quinpirole hydrochloride produced a similar effect. The drinking responses of rats to administration of angiotensin II (200 micrograms/kg, SC), isoproterenol (25 micrograms/kg, SC), and hypertonic saline (1 M NaCl, 1% of body weight, IP) were blocked by administration of quinpirole hydrochloride (7.5 mg/kg, IP). When administered alone, quinpirole had no effect on water intake. Thus, the antidipsogenic effect of quinpirole hydrochloride resembles that of clonidine and suggests that release of norepinephrine occurs centrally at some point along the final common pathway for drinking in rats.
据报道，多巴胺（DA2）激动剂盐酸喹吡罗（LY 171555）可抑制去甲肾上腺素的中枢突触前释放，该作用类似于α2肾上腺素能受体激动剂可乐定的作用。由于可乐定对所有类型的实验性诱导饮水均有抗利尿作用，因此这些实验的目的是确定给予盐酸喹吡罗是否产生类似作用。给予盐酸喹吡罗（7.5mg/kg，腹腔注射）可阻断大鼠对给予血管紧张素II（200μg/kg，皮下注射）、异丙肾上腺素（25μg/kg，皮下注射）和高渗盐水（1M NaCl，体重的1%，腹腔注射）的饮水反应。单独给予时，喹吡罗对水摄入量无影响。因此，盐酸喹吡罗的抗利尿作用类似于可乐定，提示去甲肾上腺素的释放在大鼠饮水的最终共同途径的某个中枢点发生。
